Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 19/20 | 0.48 |
| ▸ | GPR183 | P32249 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL145842 | 1.00 | GPR119 (0.48) | GPR119GPR183KCNH2CNR2 | |
| SCHEMBL119721 | 0.87 | GPR119 (0.46) | GPR119GPR183KCNH2 | |
| SCHEMBL149049 | 0.87 | GPR119 (0.46) | GPR119GPR183KCNH2 | |
| SCHEMBL147123 | 0.84 | GPR119 (0.46) | GPR119GPR183KCNH2 | |
| SCHEMBL120990 | 0.84 | GPR119 (0.46) | GPR119GPR183KCNH2 | |
| SCHEMBL458932 | 0.84 | GPR119 (0.53) | GPR119GPR183KCNH2CNR2 | |
| SCHEMBL120962 | 0.83 | GPR119 (0.49) | GPR119GPR183KCNH2CNR2 | |
| SCHEMBL145882 | 0.83 | GPR119 (0.49) | GPR119GPR183KCNH2CNR2 | |
| SCHEMBL147663 | 0.82 | GPR119 (0.44) | GPR119GPR183KCNH2 | |
| SCHEMBL121184 | 0.82 | GPR119 (0.44) | GPR119GPR183KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| EP-2406251-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Prosidion Limited (GB) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010103334-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, FFAR2, GPBAR1 | GPR119 1/4885GPR183 48/4885KCNH2 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.